These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 8838721)

  • 1. Pentamidine isethionate as secondary prophylaxis against visceral leishmaniasis in HIV-positive patients.
    Pérez-Molina JA; López-Vélez R; Montilla P; Guerrero A
    AIDS; 1996 Feb; 10(2):237-8. PubMed ID: 8838721
    [No Abstract]   [Full Text] [Related]  

  • 2. Secondary prophylaxis for visceral leishmaniasis in HIV-infected individuals.
    Pérez-Molina JA; López-Vélez ; Guerrero A
    Am J Med; 1997 Jan; 102(1):132. PubMed ID: 9209216
    [No Abstract]   [Full Text] [Related]  

  • 3. Use of Pentamidine As Secondary Prophylaxis to Prevent Visceral Leishmaniasis Relapse in HIV Infected Patients, the First Twelve Months of a Prospective Cohort Study.
    Diro E; Ritmeijer K; Boelaert M; Alves F; Mohammed R; Abongomera C; Ravinetto R; De Crop M; Fikre H; Adera C; Colebunders R; van Loen H; Menten J; Lynen L; Hailu A; van Griensven J
    PLoS Negl Trop Dis; 2015; 9(10):e0004087. PubMed ID: 26431253
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pentamidine isethionate as treatment and secondary prophylaxis for disseminated cutaneous leishmaniasis during HIV infection: case report.
    Calza L; Marinacci G; Manfredi R; Colangeli V; Fortunato L; Chiodo F
    J Chemother; 2001 Dec; 13(6):653-7. PubMed ID: 11806628
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pentamidine as secondary prophylaxis for visceral leishmaniasis in the immunocompromised host: report of four cases.
    Patel TA; Lockwood DN
    Trop Med Int Health; 2009 Sep; 14(9):1064-70. PubMed ID: 19552658
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment of visceral leishmaniasis with intravenous pentamidine and oral fluconazole in an HIV-positive patient with chronic renal failure--a case report and brief review of the literature.
    Rybniker J; Goede V; Mertens J; Ortmann M; Kulas W; Kochanek M; Benzing T; Arribas JR; Fätkenheuer G
    Int J Infect Dis; 2010 Jun; 14(6):e522-5. PubMed ID: 19726213
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prophylaxis of visceral leishmaniasis in human immunodeficiency virus-infected patients.
    Laguna-del-Estal P; Moya-Mir MS
    Am J Med; 1997 Feb; 102(2):222. PubMed ID: 9217577
    [No Abstract]   [Full Text] [Related]  

  • 8. Case Report: Intravenous Pentamidine Rescue Treatment for Active Chronic Visceral Leishmaniasis in an HIV-1 Infected Patient.
    Chechi F; Corsi P; Bartolozzi D; Gaiera G; Bartoloni A; Zammarchi L
    Am J Trop Med Hyg; 2021 Nov; 106(2):639-642. PubMed ID: 34781255
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long term outcomes and prognostics of visceral leishmaniasis in HIV infected patients with use of pentamidine as secondary prophylaxis based on CD4 level: a prospective cohort study in Ethiopia.
    Diro E; Edwards T; Ritmeijer K; Fikre H; Abongomera C; Kibret A; Bardonneau C; Soipei P; Mutinda B; Omollo R; van Griensven J; Zijlstra EE; Wasunna M; Alves F; Alvar J; Hailu A; Alexander N; Blesson S
    PLoS Negl Trop Dis; 2019 Feb; 13(2):e0007132. PubMed ID: 30789910
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment of visceral leishmaniasis in a patient with AIDS with antimony and gamma-interferon: remission and prevention of relapse by maintenance therapy with weekly pentamidine.
    Lustig V; Kager PA; Meenhorst PL
    Neth J Med; 1995 Aug; 47(2):66-9. PubMed ID: 7566284
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Discontinuation of secondary anti-leishmania prophylaxis in HIV-infected patients who have responded to highly active antiretroviral therapy.
    Berenguer J; Cosín J; Miralles P; López JC; Padilla B
    AIDS; 2000 Dec; 14(18):2946-8. PubMed ID: 11153679
    [No Abstract]   [Full Text] [Related]  

  • 12. Serial use of pentamidine and miltefosine for treating Leishmania infantum-HIV coinfection.
    Faucher JF; Morquin D; Reynes J; Chirouze C; Hoen B; Le Moing V
    Parasitol Int; 2016 Oct; 65(5 Pt A):444-6. PubMed ID: 27353022
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A case report of visceral leishmaniasis in Singapore.
    Abraham G; Leo YS; Singh M; Wong SY
    Ann Acad Med Singap; 1997 Sep; 26(5):713-6. PubMed ID: 9494684
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Visceral leishmaniasis in HIV-1-infected individuals: a common opportunistic infection in Spain?
    Medrano FJ; Hernández-Quero J; Jiménez E; Pineda JA; Rivero A; Sánchez-Quijano A; Velez ID; Viciana P; Castillo R; Reyes MJ
    AIDS; 1992 Dec; 6(12):1499-503. PubMed ID: 1362880
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment of visceral leishmaniasis unresponsive to pentamidine with amphotericin B.
    Mishra M
    J Assoc Physicians India; 1995 Apr; 43(4):306. PubMed ID: 8713286
    [No Abstract]   [Full Text] [Related]  

  • 16. Leishmaniases and HIV/AIDS co-infections: review of common features and management experiences.
    Ali A
    Ethiop Med J; 2002 Apr; 40 Suppl 1():37-49. PubMed ID: 12802830
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Liposomal Amphotericin B drug access for the treatment of leishmaniasis in Brazil.
    Mistro S; Rodrigues M; Rosa L; Camargo M; Badaró R
    Trop Med Int Health; 2016 Jun; 21(6):692-3. PubMed ID: 27037644
    [No Abstract]   [Full Text] [Related]  

  • 18. Long-term Clinical Outcomes in Visceral Leishmaniasis/Human Immunodeficiency Virus-Coinfected Patients During and After Pentamidine Secondary Prophylaxis in Ethiopia: A Single-Arm Clinical Trial.
    Diro E; Ritmeijer K; Boelaert M; Alves F; Mohammed R; Abongomera C; Ravinetto R; De Crop M; Fikre H; Adera C; van Loen H; Tsoumanis A; Adriaensen W; Hailu A; Griensven JV
    Clin Infect Dis; 2018 Jan; 66(3):444-451. PubMed ID: 29020217
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Liposomal amphotericin B as first line and secondary prophylactic treatment for visceral leishmaniasis in a patient infected with HIV.
    Borrelli P; Imperato A; Murdaca G; Scudeletti M
    Ann Ital Med Int; 2000; 15(2):169-71. PubMed ID: 10920508
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Diffuse cutaneous dissemination of visceral leishmaniasis during human immunodeficiency virus (HIV) infection, despite negligible immunodeficiency: repeated failure of liposomal amphotericin B administration, followed by successful long-term pentamidine and paromomycin administration.
    Manfredi R; Marinacci G; Calza L; Passarini B
    Int J Antimicrob Agents; 2008 Jun; 31(6):590-2. PubMed ID: 18456464
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.